<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793320</url>
  </required_header>
  <id_info>
    <org_study_id>16239-01</org_study_id>
    <nct_id>NCT05793320</nct_id>
  </id_info>
  <brief_title>Carpal Tunnel Release With Risk Factors for Amyloidosis</brief_title>
  <official_title>Prospective Histopathologic and Clinical Evaluation of Patients Undergoing Carpal Tunnel Release With Risk Markers for Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bilateral carpal tunnel syndrome has been demonstrated in previous literature to be a warning&#xD;
      sign for potential amyloidosis. One study has been performed in which patients with bilateral&#xD;
      carpal tunnel syndrome underwent tissue biopsy (either tendon sheath or transverse carpal&#xD;
      ligament) at the time of carpal tunnel release to determine the strength of association as&#xD;
      well as most common subtypes. However, no study has been done demonstrating whether or not&#xD;
      patients with amyloid-positive carpal tunnel biopsy would benefit from an early referral to&#xD;
      cardiology for a work-up of potential cardiac amyloidosis. In our study, patients with&#xD;
      bilateral carpal tunnel symptoms who are indicated for carpal tunnel release would be&#xD;
      identified in clinic and undergo biopsy for congo red staining at the time of surgery. All&#xD;
      patients with positive biopsy results would be referred to cardiology. Outcomes would include&#xD;
      the rate of amyloid positivity, common subtypes, and echocardiographic findings after cardiac&#xD;
      referral.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of amyloid positivity</measure>
    <time_frame>Biopsy sent for testing immediately after the procedure</time_frame>
    <description>How many patients who participate in study have positive biopsy for amyloidosis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Carpal Tunnel Release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carpal Tunnel Release Surgery</intervention_name>
    <description>Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.</description>
    <arm_group_label>Carpal Tunnel Release</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Positive screening is defined as two characteristics from Tier 1 or one characteristic from&#xD;
        Tier 1 and one from Tier 2 Tier 1&#xD;
&#xD;
          -  Male &gt; 50 years old&#xD;
&#xD;
          -  Female &gt; 60 years old&#xD;
&#xD;
          -  Bilateral carpal tunnel symptoms or prior release surgery Tier 2&#xD;
&#xD;
          -  Spinal stenosis&#xD;
&#xD;
          -  History of biceps tendon rupture&#xD;
&#xD;
          -  Atrial fibrillation or flutter (active or previous history)&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Family history of transthyretin amyloidosis (ATTR)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to follow up with cardiology.&#xD;
&#xD;
          -  Previous diagnosis of cardiac amyloidosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males older than 50 years old and females older than 60 years old are eligible.</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Day, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hardy Evans, MD</last_name>
    <phone>313-916-2600</phone>
    <phone_ext>ask for ortho</phone_ext>
    <email>hevans3@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Day, MD</last_name>
    <phone>3135956428</phone>
    <email>cday9@hfhs.org</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 16, 2023</study_first_submitted>
  <study_first_submitted_qc>March 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Charles S Day</investigator_full_name>
    <investigator_title>Interim Chairman &amp; Medical Director, Professor of Orthopaedic Surgery, Department of Orthopaedic Surgery &amp; Service Line, Wayne State University School of Medicine, Henry Ford Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

